Author

M. Vassar

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

AI Clinical Trials Registered on ClinicalTrials.gov Showed Persistent Misalignment with Global Disease Burden, 2010-2026.

OBJECTIVE To determine whether artificial intelligence (AI) clinical trial activity aligns with global disease burden, and whether the 2023 launch of a global AI health equity initiative was associated with a reorientation of research priorities. STUDY DESIGN AND SETTING We conducted a cross-sectional metaresearch st...

K. Kirby, Caden Forbes, T. Livsey et al. · Journal of Clinical Epidemio... · 0 citations

Open access Sep 2026

Core Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study.

INTRODUCTION Randomized controlled trials (RCTs) are the gold standard in oncology for the discovery of new therapeutic approaches and treatment management. As medicine takes a more patient-centered approach, patient-reported outcomes (PROs) have become imperative, particularly in clinical trials. The need for standard...

A. Douglas, Ty Moore, Griffin K. Hughes et al. · Clinical Breast Cancer · 0 citations

Review Open access Aug 2026

Safety reporting in chronic kidney disease clinical trials: a comparison of ClinicalTrials.gov registries and published reports

Transparent reporting of adverse events (AEs) is essential for evaluating the safety of interventions from chronic kidney disease (CKD), a population especially vulnerable to treatment-related harm because of polypharmacy, reduced renal clearance, and high comorbidity burden. Since 2007, the FDA Amendments Act (FDAAA 8...

Nevada Denton, Lydia Hashemi, Daniel Archer et al. · Clinical Kidney Journal · 0 citations